Early Diagnosis of Pancreatic Cancer Duodenal Fluid-Based Biomarker Exploratory Study

Part of paid clinical trials in Aurora, Colorado.

Sponsor
Do Hyun Park
Study ID
NCT07030348
Status
Recruiting
Apply to this trial

Conditions

  • Pancreatic Cancers
  • Pancreatic Diseases

Eligibility Criteria

Sex
ALL
Age
19 Years - N/A
Healthy Volunteers
Accepted

Study Details

Purpose Pancreatic cancer is the fourth leading cancer-related mortality disease in the United States, with a five-year survival rate of 11%, and only 10 15% of all pancreatic cancer patients are operable or borderline operable. Therefore, there is an unmet need for early diagnosis of pancreatic cancer; however, biomarkers related to this are not well understood. This study aims to identify biomarkers for the early diagnosis of pancreatic cancer through duodenal pancreatic juice, which can be easily obtained through an endoscopy.

Key Dates

Start date
Jan 2, 2024
Status verified
Jun 2025
Primary completion
Dec 31, 2026
Completion
Dec 31, 2026

Study Design

Enrollment
263 participants (estimated)

Arms

  • Arm: Pancreatic Cancer Group (DP)
    Participants with a biopsy with proven stage I-IV pancreatic ductal adenocarcinoma (PDAC), or with suspected pancreatic cancer on imaging and scheduled for an endoscopic ultrasound-guided pancreatic biopsy.
  • Arm: Non-Pancreatic Cancer Group (DC)
    Participants with pancreatic cystic tumors or with acute or chronic pancreatitis, or with no evidence of a pancreatic disease

Primary Outcome Measure

Identification of Biomarkers for Early Pancreatic Cancer Detection [ Time Frame: Up to 1 year from baseline ]

Central Contacts

Locations (2)

FacilityCityStateZIPSite coordinators
University of Colorado HospitalAuroraColorado80045-
Cleveland ClinicClevelandOhio44195-

Find similar trials in Aurora, CO

By research site
University of Colorado Hospital· Aurora, COCleveland Clinic· Cleveland, OH

Related Studies